Tucidinostat plus CHOP for newly diagnosed PTCL-TFH lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with a type of T-cell lymphoma called PTCL with follicular helper T-cell phenotype
- You have not had any previous treatment for your lymphoma
- You have at least one tumor that can be measured on scans
- Your blood counts and liver/kidney function are within certain ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (golidocitinib) combined with standard chemotherapy for people with a specific type of lymphoma that hasn't been treated before. The goal is to see if adding the pill helps control the cancer better than chemo alone.
This study tests a new drug (BEBT-908) combined with standard chemotherapy for people with untreated peripheral T-cell lymphoma. The goal is to see if the combination helps shrink tumors.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Hear when a new Lymphoma, T-Cell, Peripheral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.